title: Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis.
abstract: OBJECTIVE
  To report combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide injection for subfoveal neovascularization secondary to bilateral idiopathic juxtafoveal telangiectasis.
  
  
  METHODS
  Interventional case report.
  
  
  METHODS
  A patient with a subfoveal neovascularization secondary to bilateral idiopathic juxtafoveal telangiectasis was treated with PDT plus an intravitreal injection of 4 mg of triamcinolone acetonide.
  
  
  RESULTS
  Leakage in the late-phase of fluorescein angiography resolved with attenuation of telangiectatic vessels and improvement in visual acuity from 20/200 to 20/50. At 9 months post-treatment, recurrent leakage was treated with repeat PDT and intravitreal triamcinolone. One year after initial presentation, visual acuity was 20/60 with no leakage on fluorescein.
  
  
  CONCLUSIONS
  Combined treatment with PDT and intravitreal triamcinolone acetonide resulted in regression of a subfoveal neovascular membrane and improvement in visual acuity during the course of follow-up.
authors.affiliation: Vitreous, Retina, Macula Consultants of New York, New York, USA.
authors.forename: Lindsay M
authors.initials: LM
authors.lastname: Smithen
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
mesh_terms: D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy*; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D013684:Telangiectasis / Q000150:complications / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D000077362:Verteporfin; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide